Výsledky vyhledávání - "Catherine T Frenette"

Akademický článek

Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel

Autor: Jennifer Pate, Juilo A Gutierrez, Catherine T Frenette, Aparna Goel, Sonal Kumar, Richard A Manch, Edward A Mena, Paul J Pockros, Sanjaya K Satapathy, Kidist K Yimam, Robert G Gish

Publikováno v: BMJ Open Gastroenterology, Vol 6, Iss 1 (2019)

Background and aimsThis article provides expert guidance on the management of pruritus symptoms in patients receiving obeticholic acid (OCA) as treatment for primary biliary cholangitis (PBC). PBC is a chronic, autoimmune cholestatic liver disease th

Externí odkaz: https://doaj.org/article/e72f88a6fde64c119109678fa6898a94

Zobrazit plný text záznamu

Akademický článek

Safety and efficacy of pharmacologic weight loss in patients with cirrhosis

Autor: Ali Y. Fakhreddine, Samantha Bagsic, Ken Fujioka, Catherine T. Frenette

Publikováno v: Obesity Science & Practice, Vol 7, Iss 2, Pp 159-167 (2021)

Abstract Background Obesity poses unique risks in patients with advanced liver fibrosis; however, given surgical risks of bariatric surgery in cirrhosis treatment recommendations are currently limited to lifestyle interventions. This study seeks to i

Externí odkaz: https://doaj.org/article/365746b73f404236875b788dba1dad33

Zobrazit plný text záznamu

Akademický článek

A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk

Autor: Catherine T. Frenette, MD, Ari J. Isaacson, MD, Irene Bargellini, MD, Sammy Saab, MD, MPH, Amit G. Singal, MD, MS

Publikováno v: Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 3, Iss 3, Pp 302-310 (2019)

Hepatocellular carcinoma (HCC) arises in the context of cirrhosis and chronic hepatitis B virus (HBV) infections, and the diagnosis is often made at advanced stages. Because early-stage diagnosis improves survival, guidelines recommend screening pati

Externí odkaz: https://doaj.org/article/30e0229f88314522bdfe9d80df8c347e

Zobrazit plný text záznamu

EARLY EXPERIENCE OF USTEKINUMAB FOR TREATMENT OF MODERATE-TO-SEVERE INFLAMMATORY BOWEL DISEASE IN PATIENTS POST-LIVER TRANSPLANT

Autor: Pooja Magavi, Catherine T. Frenette, Melissa Ferrari, Gauree G. Konijeti

Publikováno v: Gastrointestinal Endoscopy. 95:AB28-AB29

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4853155f885c229a84cd9e3d596b363f
https://doi.org/10.1016/j.gie.2022.04.116

Zobrazit plný text záznamu

Sa1457: RIFAXIMIN PLUS LACTULOSE IS MORE EFFICACIOUS THAN LACTULOSE ALONE FOR RISK REDUCTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A SUBGROUP ANALYSIS BY VIRAL OR ALCOHOL CIRRHOSIS ETIOLOGY

Autor: Jasmohan S. Bajaj, Arun J. Sanyal, Vinay Sundaram, Catherine T. Frenette, Zeev Heimanson, Robert J. Israel, Robert S. Brown

Publikováno v: Gastroenterology. 162:S-1176

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb4bd0aece2ac8d9a35e17cd0d3ed89c
https://doi.org/10.1016/s0016-5085(22)63502-9

Zobrazit plný text záznamu

A phase 1 study of ABX196 in combination with nivolumab in patients with previously treated hepatocellular carcinoma (HCC)

Autor: Darren Sigal, Munveer Singh Bhangoo, Catherine T. Frenette, Sunyoung S. Lee, Christine Fark, Paul Gineste, Anais Vissian, Luc Teyton, Tillman E. Pearce, Ahmed Omar Kaseb

Publikováno v: Journal of Clinical Oncology. 40:429-429

429 Background: ABX196, a synthetically modified α-galactosylceramide (α-GalCer), activates invariant NKT (iNKT) cells and produced anti-tumor activity in Hepa 106 xenograft HCC models. Pre-administration of anti-PD1 antibodies prevented α-GalCer-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::682e70039d078355263bce4405840e8b
https://doi.org/10.1200/jco.2022.40.4_suppl.429

Zobrazit plný text záznamu

Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study

Autor: Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Philippe Merle, Masafumi Ikeda, Gianluca Masi, Catherine T. Frenette, Yoon Jun Kim, René Gerolami, Masayuki Kurosaki, Kazushi Numata, Julia Pisarenko, Kirhan Ozgurdal, Shukui Qin

Publikováno v: Journal of Clinical Oncology. 40:433-433

433 Background: Regorafenib improved OS versus placebo in patients with uHCC who progressed on prior sorafenib in the RESORCE trial (Bruix J, 2017). An interim analysis of the observational REFINE study supported the safety and effectiveness of regor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ffd29bf44d84222f4e390993aff43f0f
https://doi.org/10.1200/jco.2022.40.4_suppl.433

Zobrazit plný text záznamu

Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection

Autor: Sirisha, Grandhe, Catherine T, Frenette

Publikováno v: Gastroenterologyhepatology. 13(7)

Chronic hepatitis C virus (HCV) infection has generally been associated with a slightly increased risk of developing hepatocellular carcinoma (HCC). For the past several decades, most patients with chronic HCV cirrhosis have been treated with pegylat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3bfa437a6ece645dc8aeb134b2edda22
https://pubmed.ncbi.nlm.nih.gov/28867970

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání